Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 6440

X
Drug Profile

RG 6440

Alternative Names: RG-6440; RO-7496353; SOF-10

Latest Information Update: 11 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Genentech; Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Oct 2023 Phase-I clinical trials in Solid tumours (Combination therapy, In adults, Recurrent, In the elderly, Late-stage disease, Metastatic disease) in Japan (IV) (NCT05867121)
  • 23 May 2023 Roche plans a phase I trial for Solid tumours (Combination therapy, In adults, In the elderly, Late-stage disease, Metastatic disease) (IV) in July 2023 (NCT05867121)
  • 22 Oct 2021 Phase-I clinical trials in Solid tumours in USA (IV) prior to October 2021 (Chugai Pharmaceutical pipeline, October 2021) (Roche pipeline, December 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top